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Referring to long-acting naltrexone implants and injections, another hot topic explored the
“curious possibility that precisely because a technology is (relatively) effortlessly effective, it is
to that degree under suspicion”. That was in relation to opioid use treatment in general; here we
focus on convicted offenders, and ask: Are we missing a trick by not pressuring opioid-
dependent offenders under supervision to take the pills or be implanted/injected with
naltrexone?
Particularly for offenders, naltrexone seems the perfect medication for promoting abstinence
from heroin and allied drugs – a pill taken daily or just twice a week which makes heroin use a
disappointment rather than a ‘high’. Free itself of psychoactive effects, naltrexone commandeers
and blocks the neural receptors targeted by opiate-type (‘opioid’) drugs. A chemical instead of a
physical shackle, it seems in tune with the deprivation of liberty imposed on offenders because it
deprives them of opioid experiences rather than providing these in the form of substitute
opioids. At its most optimistic, the hope and expectation is that long-acting naltrexone implants
will result in patients “learning to abstain successfully”, likened to learning to speak a foreign
language fluently in that “It is not enough simply to know the foreign words, or the social and
psychological techniques for resisting temptation. What matters is practice and the ability to use
those words or techniques not just correctly and appropriately but automatically”. However,
lasting effects are not necessarily critical to treatment linked to a probation or parole order.
Judges just need to be persuaded that treatment is likely to do as good a crime-prevention job
as prison – that it will prevent or keep offending to a minimum for as long as the offender would
have been locked up, rarely more than a year for non-violent drug-related offences.
Yet compared to substitute medications like methadone, naltrexone is rarely used inside or
outside the criminal justice system. One reason is a limitation applicable to any medication
which deprives patients of valued experiences: the more effective it is, the more patients simply
refuse it or quickly abandon the treatment. Again this seems to make the treatment suitable for
sentenced offenders, by definition already coerced into doing things they would not otherwise
do. Let’s examine this apparently suitable marriage between treatment and patient, and ask
ourselves if by under-using it, we are missing what could be the most effective way yet to break
opioid-dependent offenders of a crime-generating habit.
Overcoming resistance
There are at least three ways to overcome reluctance to start or continue with naltrexone. For
convicted offenders, these could coalesce into a powerful treatment. The first way is technical –
the availability of long-acting naltrexone products which once inserted in the body more or less
consign the patient to a period when opiate effects are blocked; they cannot (or not easily) stop
taking the medication, even if they want to. An implant inserted under the skin blocks opiates
usually for two to six months; an intramuscular depot injection approved for medical use in the
USA and Russia lasts about a month. From cell A3 we know that among treatment populations
willing to try these products, they are more effective in preventing illegal opiate use than
naltrexone pills which patients can simply stop taking, and also more effective than placebo
versions of the implant or injection. In other words, at least while active they certainly can work
for patients motivated to return to a life free of dependence on opiate-type drugs.
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A major (but not absolute) impediment to using these products in the UK is that they
have not been licensed for medical use. They can still be and have been prescribed (1 2 3
4), but patient and doctor have to accept the added responsibility of using a product which
has not yet been certified as meeting the safety and efficacy requirements involved in
licensing.
The second way to overcome non-compliance is psychological – to engender the
motivation to take naltrexone by making it worth the patient’s while in order to gain
valued rewards or avoid aversive punishments. Third are social influences – the
availability and commitment of someone with influence over the patient who is in a
position to encourage them take the pills and monitor whether they do.
All three ways to prevent naltrexone being neutralised by non-compliance can in theory
be marshalled for opioid-dependent offenders under criminal justice supervision.
Long-acting implants or injections should be as available to them as to other patients, the
prospect of early release from prison or avoidance of a more unpalatable sentence might
be a powerful motivation-generator, while criminal justice officers – or treatment
personnel reporting to them – can insist on frequent contact to bolster motivation and
supervise administration of the pills or renewal of implants/injections.
But is it ethical?
However, because something can be done does not mean that it should be. With
naltrexone ethical misgivings about pressuring people into treatment – ultimately aimed
at benefiting not them but society at large – are sharpened by its potential danger. Any
procedure which erodes opioid-dependent patients’ capacity to tolerate high doses by
successfully interrupting use of the drugs leaves those patients at heightened risk of fatal
overdose if it does not also succeed in preventing relapse. Naltrexone may further
aggravate the risk. Experts convened by the World Health Organization have warned that
patients who stop naltrexone in order to resume heroin use can find that same ineffective
dose they took hours before is later fatal as naltrexone levels fall and the blockade
weakens. Some of the highest drug user death rates ever seen were recorded in Australia
among patients who completed detoxification and tried to avoid relapse by taking oral
naltrexone, findings explored in Effectiveness Bank analyses (1 2).
Post-detoxification overdose risk is one reason why UK national guidelines caution careful
selection of patients fully committed to abstinence and with supportive and stable social
environments available after discharge, among which may be seamless entry to
residential rehabilitation. The preparation phase and the detoxification interlude itself
should, said the guidelines, be used to bolster psychological resilience and social supports.
The problem is that heroin-dependent patients in general lack these kinds of supports,
and convicted offenders may lack them even more, raising concerns about leveraging
their restricted freedom to persuade them to accept naltrexone-based treatment.
Part-funded by US government agencies, so prominent had this question become that in
2006 an issue of the Journal of Substance Abuse Treatment devoted a special section to
“Mandating Naltrexone Among Court-Referred Patients: Is It Ethical?”
Summarised here, the supplementary text (click to
unfold ) explores these and other commentaries on
the ethics of naltrexone treatment of offenders. You
will see that there is generally agreement that given
safeguards, it is ethically defensible to offer the choice
of naltrexone-based treatment if this qualifies an
offender for a more lenient sentence than would
otherwise be imposed, such as early parole from prison
or probation instead of imprisonment. This option has even been lauded as extending the
offender’s choices rather than restricting their autonomy. Still there are concerns that
when treatment takes the form of a long-acting insert in the body which can be active for
several months, it ties the patient’s hands, preventing them terminating the treatment
even if they find they want to, and that treatment has been subverted to criminal justice
objectives rather than the good of the patient. Safeguards considered mandatory include
what in societies with treatment systems like those of the UK would be a make-or-break
condition – that naltrexone be just one of a menu of options which would include
methadone or other substitutes for illegally obtained opiates. Since the great majority of
opioid users would either choose no medication at all or methadone-type treatment rather
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than naltrexone, this is almost certain to scupper naltrexone’s chances with all but
a few offenders.
In contrast to the Hobson’s choice considered above, usually rejected as unethical is
forced treatment over which the patient has no choice – not even of the usual
sentence instead. But again there are dissenting voices, arguing that this might be
acceptable as long as by restricting the patient’s freedom to experience opioid
effects, naltrexone extends their autonomy by freeing them from the cravings that
constrict and dominate their life; “Infringing autonomy to create autonomy”. Also
the case was made that forced intervention is a more caring response than leaving
the helplessly addicted to generate their own destruction and that of others:
“Leaving … addicted people to their own destiny is not a ‘no-fault’ exercise for peers
and for society at large. The self-destruction, incarceration, or disability of a family
member does affect others.” Counter-arguments are that the ‘addict’ retains their
freedom to choose, and not having lost this, does not need it ‘restored’ by
naltrexone, that the medication has not been shown to dampen cravings which lead
to relapse when the treatment ends, and that this line of thinking would justify
ignoring patients’ wishes and forcing treatment on the over-eater or those
exhibiting obsessive-compulsive tendencies – a slippery slope to state control via
medicine displacing the (in Western cultures) valued autonomy of the individual.
Check out these powerful arguments by unfolding  the supplementary text,
preparatory to answering our final questions on where you stand on these
controversial issues.
 Close supplementary text
Kicking off the special section of the Journal of Substance Abuse Treatment, two
researchers who had provided some support for naltrexone not only saw no
serious ethical concerns, but recommended it as “the most individually and
publicly beneficial approach” to opiate-addicted non-violent offenders when the
alternative was being sent to or having to stay in prison. They pointed out its
appeal to judges and probation officers, who may see methadone or
buprenorphine as too similar to heroin itself, and to parolees and probationers
who could be imprisoned if they relapse. Nowhere did they mention the risk of
overdose if the patient does relapse after stopping naltrexone.
Without using these terms, the researchers said pressuring people to take
naltrexone can actually extend their autonomy: “For the first time, they are able
to move about their neighborhoods with no risk of heroin relapse. Some report
this as a life-changing experience.” In the same issue if the journal, medical
ethicist Arthur Caplan centred on this aside from the researchers. Adopting a
‘let’s push the boat out and see if floats’ tone, he argued that forced treatment
over which the patient has no choice – not even of the usual sentence instead –
might be considered acceptable as long as by restricting the patient’s autonomy
in this way, it extends it by “letting them be free from cravings, drives, and habits
that inhibit their capacity to make choices” – “Infringing autonomy to create
autonomy,” was how he encapsulated it.
Though floated by a “well-known and widely respected” Emeritus Professor of
Medical Ethics and Health Policy, this boat had some very large holes, responded
two respected drug misuse researchers and commentators. Robert Newman
doubted the efficacy of the treatment, but it was his more principled objections
which hit home: the treatment was for the benefit of society not the patient,
long-acting implants were inserted “for the specific purpose of rendering patients
incapable of opting out, regardless of the subjective response(s) they may have
to the medication”, and if the treatment fails, it is the patient who pays the price
of the imposition of a harsher sentence. Most fundamentally, the presumption
that drug-dependent patients have impaired autonomy which can be restored by
naltrexone is false; even in the throes of addiction, the individual remains able to
take decisions and may refuse treatment on logical grounds, and after the grip of
naltrexone has been released, the task of restoring autonomy remains because
cravings persist or return. Even if forcing naltrexone on someone did lead them
to adjust to an opioid-free life, this sort of justification “would allow one to ignore
almost any decisions made by patients” well beyond the scope of addiction
treatment.
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This “slippery slope” argument was taken up by professor of psychology
Frederick Rotgers in 2007 in a mailing list post. If bioethicists accept as a
reality drug addicts’ reports of being unable to resist their urges, they also
have to accept those of patients being treated for other compulsions, or
illogically discriminate against drug users. It follows then that over-eaters
or those with obsessive-compulsive disorders can also be medicated against
their wishes, yet in the USA this is considered unacceptable. Why the
difference? For professor Rotgers it was clear: in respect of drug use, “the
primary aim of the mandatory medication is NOT the beneficent one of
freeing the poor patient from his/her subjective compulsions to use drugs,
but rather to protect the public from the criminal behavior supposed to be
fuelled by addiction … The OCD sufferer, the binge eater, the bulimic, all
have an ethically and legally protected right to refuse treatment. The
addictive disease sufferer does not!”
In 2008, 13 doctors working in the USA saw it rather differently. From the
point of view of the clinician faced with deciding whether to provide
coerced treatment, their starting point was that in the USA, “for many
addicts, the only way they will receive treatment ‘in spite of themselves’ is
to end up in the criminal justice system, which is gradually evolving into an
involuntary treatment system”. Apart from patient autonomy, for them
“another central principle in medical ethics” was “beneficience … the duty
of health care providers to be of benefit to the patient, as well as to take
positive steps to prevent and to remove harm from the patient”. These
principles sometimes conflict, but they placed most weight on beneficience,
which may positively require the clinician to engage in coerced treatment:
“failure to increase the good of others when one is knowingly in a position
to do so (ie, to offer effective treatments) is morally wrong. As the
evidence … suggests, coercive treatments are effective … it would be
unethical to withhold [them from] patients who could benefit.” Bringing
their case vividly to life, they argued that “Leaving addicted people to their
own destiny is not a ‘no-fault’ exercise for peers and for society at large.
The self-destruction, incarceration, or disability of a family member does
affect others.” Objections on the ground of autonomy were turned on their
head and criticised as “ally[ing] themselves with the coercive forces of the
psychoactive substance” – the real autonomy-eroding villains, whose grip
means an “addicted individual may have a compromised ability to make
free, unencumbered choices. The autonomy perspective ignores the
coercive forces of acute intoxication and withdrawal, subacute anxiety and
depression, and chronic neurophysiological consequences of psychoactive
substance use.”
A practical take on naltrexone implants came from Douglas Marlowe, a
prolific and thoughtful researcher on addiction treatment and criminal
justice supervision of drug dependent offenders. Writing in 2006 before
much data was available, he thought implants more than worthy of study.
Punishment has, he said, failed or been counterproductive, while offering
rewards for good behaviour is generally unacceptable and gives the
message that one behaves well only if it is rewarded. ‘Negative
reinforcement’ in the form of early parole or diversion from criminal
prosecution “offers a practical way to steer between these barriers by
avoiding the iatrogenic [a ‘remedy’ which causes illness] effects of
punishment and by being palatable to the citizenry”. Rather optimistically,
he foresaw that because implanted naltrexone was “demonstrably
efficacious, nonpsychoactive, and has few negative side effects … it would
be unlikely to invoke the same types of legal and ethical objections that
have traditionally been raised against the use of psychoactive medications
with vulnerable populations of institutionalized offenders.”
Some of the arguments addressed so far relate mainly to forced treatment,
but professor Marlowe was talking about the Hobson’s choice posed both in
the UK and USA, when agreeing to naltrexone qualifies an offender for a
more lenient sentence than would otherwise be imposed, such as probation
instead of imprisonment or early parole from prison. Another article in the
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special section of the journal argued that in these circumstances,
naltrexone opens up options for the offender, actually extending
their freedom of choice. Based on US law, his opinion was that “as
long as the treatment is medically appropriate in the offender’s case
and … the offender has been fully informed about what is expected
of him,” these agreements should be legally acceptable and,
moreover, to refuse to make this opportunity available would be to
discriminate against opioid-dependent offenders. In contrast, when
the offender would in any event be sentenced to probation or offered
parole, insisting that this must incorporate naltrexone treatment
could only be justified if for that individual it was essential to
prevent criminality in the form of illegal opiate use, and we could be
confident that it would achieve this objective – high hurdles given
the availability of other treatments and naltrexone’s slim research
record with offenders.
From a British perspective, a criminologist specialising in substance
misuse also broadly endorsed the ethical credentials of offering a
choice between the normal sentence and a less restrictive one
incorporating treatment. Basing his arguments on “international
human rights law and leading codes of medical ethics,” professor
Alex Stevens also talked of the “opportunity” opened up by offering
a treatment plus probation/parole package to drug-dependent
offenders who otherwise face a more restrictive sentence, likely to
be those convicted of relatively serious theft or other revenue-
raising crimes.
But for professor Stevens, among the many conditions to be satisfied
was that “the person is offered a choice between forms of treatment
that are adequate and humane, according to his or her individual
needs and wishes,” and that treatment is the objective, not
punishment. Experts commissioned by the World Health
Organisation also said ethical treatment would entail offenders being
offered a “range of treatments from which they can choose”. Since
substitute opioids like methadone have at least as good a record at
preventing illegal opiate use as naltrexone, on these grounds it
would be unethical to exclude these options if they are available
within that society. Research tells us that given this choice, few
would opt for naltrexone. This may be one reason why the treatment
choices open to offenders sometimes consist of naltrexone or
nothing. But another reason is that after perhaps initial ‘testing’ of
the blockade, naltrexone promises to eliminate illegal opioid use in a
way methadone does not, unless the doses are so high that ‘on top’
use is ineffective. Giving drug-seeking offenders lots of what they
want free of charge in the form of the very type of drug which led
them to offend rankles with some, no matter how effectively it curbs
criminality.
Though as mentioned above it is legal to prescribe products which
have not been licensed for medical use, the ethics of doing so have
been questioned by a quartet including some of Australia’s
best-known drug misuse researchers. Australia is where a naltrexone
implant was developed and in some areas widely used despite (as in
the UK) not having gone through the normal process for obtaining a
product licence for medical use. A heated issue in that country, in
2008 the critics argued that treatment-seeking opioid users “should
be afforded the same regulatory protections as people with any other
physical or mental disorder … Given the absence of data on safety
and efficacy, it is of major concern that more than 1500 Australian
opioid-dependent patients have been, and continue to be, given
implantable naltrexone in the absence of its registration as a
therapeutic good.” Their argument would apply also to the UK: “We
believe that it is currently ethically questionable for practitioners in
any country to offer this treatment … outside the setting of
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randomised controlled trials”. That last comment takes us to
the trials which have been done – important not just to
establish effectiveness, but also the ethical defensibility of
pressuring offenders to accept naltrexone; there is general
agreement that only if a treatment actually has a good chance
of helping is there any possible justification for coercing or
mandating its acceptance.
 Close supplementary text
Does it work?
Given ethical concerns, no product licence, and the treatment’s
lack of appeal to many prospective patients, it is no surprise that
both in the USA and the UK naltrexone is very much a minority
option, even for offenders. In 2004, Dr Colin Brewer, whose
private clinic provided long-acting naltrexone, recorded that
despite “considerable benefits from probation-linked naltrexone,”
researchers evaluating court-ordered drug treatment in England
found that only one offender in their sample had received
naltrexone.
Another sign of how rarely this option has been used is that in
2006 a thorough search for randomised trials among offenders
found just one dating from 1997 (it is listed above). A fresh
search ending in 2014 found just three randomised trials. Even
then the 1997 trial remained the most important test of
naltrexone added to ‘treatment as usual,’ though it had been
supplemented by a another US trial published in 2010.
These two trials are critical because they sampled offenders
living in the community under criminal justice supervision, the
main use envisaged for naltrexone. Both recorded marginally
significant reductions in the proportions of offenders who
violated parole attributable to adding an oral naltrexone
programme to usual procedures. The later review found these
results amalgamated to a clearly significant reduction. Parole
violation was the only measure of criminality which could be
amalgamated, but in the 2010 study there were others which
gave a different picture – notably records rather than
self-reports of parole violations (not significantly reduced) and
the non-significantly but considerably more (32% v. 10%)
naltrexone offenders charged with drug offences during the
six-month follow-up.
These and other studies are analysed below unfold 
supplementary text. As a whole they show how few (previously)
opioid-dependent offenders opt for naltrexone even when opioid
substitutes are not on offer, that when naltrexone administration
is supervised, and when offenders want it, have strong
incentives to comply, and the treatment is active, it helps
suppress opioid use and prevent parole or probation violations,
affording offenders opportunities for learning to live opioid-free
in the community which may otherwise be denied them. Without
these conditions, rejection and drop-out from the programmes
becomes the norm. Even with them, there seems no evidence
that the substance use and parole/probation violation gains
made while naltrexone is active persist after treatment ends, or
(perhaps related) that they automatically extend to the
stabilisation and improvement of other aspects of the patients’
lives.
As with the ethical considerations outlined above, check out
these findings in greater detail by unfolding  the
supplementary text, preparatory to answering our final
questions on where you stand on naltrexone treatment for
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offenders.
 Close supplementary text
Published in 1997, the first randomised trial of
naltrexone for opiate-dependent offenders (listed
above) recruited 51 of 300 potentially eligible offenders
on probation or parole and being supervised by the
substance abuse arm of the federal probation service in
Philadelphia. Nearly all the rest declined this better-
than-even chance (by design, twice as many offenders
were allocated to naltrexone as to the control group) of
extra support to stay opiate-free. The 51 were randomly
allocated to fairly intensive weekly contact with their
probation officers during which they would be urine
tested, or to this plus twice-weekly naltrexone
administered by researchers in the same building and at
the same time as one of their probation appointments.
The researchers also urine-tested the offenders, the
results of which were kept confidential. Though over the
six months of the follow-up a higher proportion of
naltrexone patients were retained in the study (52% v.
33%), on average they were much less likely (8% of
tests v. 30%) to test positive for opiates – a statistically
significant difference unlikely to be due to chance and
attributed to the naltrexone supplement. There were no
signs that naltrexone-blocked offenders had
compensated by switching to other drugs. Greater rates
of non-attendance and illegal drug use probably
contributed to fact that over the six months, 56% of the
probation-only offenders were sent back to prison for
violating probation but just 26% also administered
naltrexone, another statistically significant difference.
The study exemplifies the conclusion that naltrexone
has a role among closely monitored patients who have
much to lose (in this case, their freedom) from dropping
out of treatment and returning to opiate use, especially
when pill-taking is supervised – but also indicates that
even then, few offenders may opt to have their freedom
to use opiates pharmacologically curtailed.
The contrast between findings in this study and one
published in 2010 illustrates the importance of
monitoring. Encouraged by their earlier findings, the
same research group tried psychosocial treatment with
versus without naltrexone for opiate-dependent
offenders under legal supervision in the community,
though this time they were all already in intensive
treatment for their drug problems. As before, over an
intended six months of treatment and follow-up
assessments, the drug was administered twice-weekly
by the research team, but at a slightly higher dose
(totalling 300 mg a week rather than 250 mg). In both
the naltrexone and the no-naltrexone groups, just
under a third of patients completed treatment; final
assessments could be made on fewer than 40 of the 111
participants. On crime there was a mixed picture.
Naltrexone did not significantly affect recorded
criminality, though non-significantly more (32% v.
10%) naltrexone offenders were charged with drug
offences. Favouring naltrexone, the offenders’ own
accounts indicated that with naltrexone they were
significantly less likely to have violated parole. When it
came to drug use, while retained in treatment the
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naltrexone patients submitted significantly more
opiate-free urines, indicating that relapse to
opiate use was substantially more common
without the support of naltrexone. However, once
missing tests were assumed indicative of opiate
use, this result was overwhelmed by the high
drop-out rate; naltrexone still had the advantage,
but it was no longer statistically significant. By
the end of the six months no significant
differences remained in opiate use, even among
patients still in treatment.
With or without naltrexone, in this study it
seemed that the minority of offenders who
completed treatment rarely used opiates. In
contrast, before they left, naltrexone helped the
majority who later dropped out to stay
opiate-free. Reading between the lines, offenders
who were predisposed to return to opiate use
were helped by naltrexone as long as they stayed
in treatment, while those more ‘compliant’,
stable, and determined to complete treatment,
did not need this support.
When the researchers asked themselves why the
results were less convincing than in their earlier
study, they highlighted the much lesser degree of
criminal justice supervision and consequently the
lower risk of non-compliance being spotted and
resulting in sanctions. In the later study, only
among the relatively closely supervised and
regularly urine-tested offenders referred from a
drug court did naltrexone help patients complete
treatment – 57% did so compared to none not
administered naltrexone, though numbers were
small. The practice implications were that “in
order to be successful, oral naltrexone in
probationers and parolees requires more
supervision than is typically available in the
criminal justice system”. Neither of the reports on
the trials documented non-fatal overdose events
or deaths.
Prison and compulsory detention
Turning from community supervision to prisons,
what seems the only remaining randomised trial
using the oral form of naltrexone among
offenders was conducted in Australian prisons
between 2002 and 2004. Consenting prisoners
were randomly allocated to oral naltrexone,
methadone maintenance, or drug-free
counselling. Arrangements were made for free-of-
charge continuation of naltrexone after release.
Nevertheless the trial foundered on the
unwillingness of the prisoners to actually take
naltrexone. Only 9 out 66 assigned to the
treatment started naltrexone and only 14 out of
204 opted for the treatment over the entire
two-year study period; of those, just one stayed
in treatment for six months, far worse figures
than for methadone. For the researchers, the
most likely explanation for the findings was that
“inmates were not subject to coercion or
incentives to enter and stay on naltrexone
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maintenance. In the absence of such
incentives, opioid dependent inmates showed
a preference for agonist treatment including
methadone maintenance and buprenorphine
maintenance. Many inmates who achieved
abstinence preferred no treatment or drug
free counselling over naltrexone. The overall
conclusion of the study was that poor patient
acceptability and retention did not support
oral naltrexone in this treatment group.”
Randomised trials have been supplemented
by studies of how supervised offenders
respond to naltrexone in normal practice.
Listed above, the first documented use of
naltrexone among offenders appears to have
been in Nassau County Jail in New York state
in the USA, where from 1972 a work-release
programme began to accept opiate-
dependent inmates as long as they agreed to
take oral naltrexone (1 2 3 4; unclear
whether paper 4 involves offenders).
Prisoners in general were already allowed
out to work, earn and save money, but
previously opiate-dependent inmates had
been excluded because they “may be
tempted to get high when faced with old
friends and familiar situations”. Monitored
administration of naltrexone generally twice
a week plus random urine-testing was seen
as qualifying them for work-release
privileges because (perhaps after a few
attempts which were not heavily sanctioned)
it would prevent them giving in to
temptation.
Blocking was, however, not seen as a
complete solution. At the same time
extensive support was provided to overcome
dependence and reintegrate into society,
including weekly counselling, vocational
rehabilitation assessments, possibly financial
support for training, pre-release referrals
and community contacts, and help with
finance, employment, family relationships,
legal issues, and finding appropriate
treatment. To aid the latter patients were
often taken round the neighbouring
naltrexone treatment clinic. About a fifth
continued their treatment on release.
Though accepting that the opposing
approach of prescribing opioid substitutes
also has its place, according to officials from
the county’s Department of Drug and Alcohol
Addiction (citations above), the net result
was that “The addicted inmate is provided
access to correctional program options that
were previously out of reach, including the
possibility of firmer anchoring to family and
other aspects of life in the community.” From
being excluded and as too high a risk,
naltrexone-treated participants were found
to transgress or drop-out no more than
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other work-release prisoners: “The
correctional administration now views
naltrexone program participants as among
the most trustworthy in the facility.”
Like the New York programme, one in
Singapore did not penalise initial lapses to
heroin use because these were considered
potentially valuable learning, demonstrating
to the patients that heroin use was pointless
while taking naltrexone and ‘extinguishing’
conditioned responses associating heroin use
with rewarding experiences. Supervised
consumption of oral naltrexone was added to
an existing programme which detained
opioid-dependent adults in a rehabilitation
centre and after a year monitored them in
the community. Release from the centre
could be obtained in six months instead if
patients opted for a year on naltrexone. Of
those who did, three-quarters were retained
though the first year of the community
phase of the rehabilitation compared to
about a quarter in the preceding three years
when naltrexone was not on offer. By the
end of the following year when naltrexone
treatment had stopped but drug testing
continued, 32% were still thought free of
opioids. Fears of serious side-effects from
naltrexone proved unfounded, and the
report does not mention any overdoses
among the adverse events recorded.
In Bristol in England a drug treatment
service mounted a naltrexone programme
for prisoners who had been using both crack
cocaine and heroin. The intention was to use
both oral and long-acting forms of the drug
but in the event only the oral form was
available. An evaluation found that 172
referrals led to just 51 patients being
inducted on to naltrexone, of whom only
eight completed three months on naltrexone
and two nine months. A major impediment
was the inability to induct most of the
referrals while still in prison. When induction
was delayed until after release just a quarter
took up the opportunity, possibly partly
because the induction clinic was not
conducive to abstinence-oriented treatment.
In contrast, 9 of the 10 inducted in prison
continued treatment on release. Lacking
coercion or rewards for compliance, it is
unlikely that the programme would in any
event have succeeded with other than a
minority of offenders, but any chances it had
were stymied by work pressures and
organisational shortcomings in both prison
and clinic.
Long-acting naltrexone
Like the earlier US studies, a US trial listed
above compared usual procedures (in this
case drug counselling) to these
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supplemented by naltrexone for offenders
with a history of opioid dependence who
were living in the community under criminal
justice supervision. The major difference was
that naltrexone was in a long-acting form
injected into the body, whose effects last
about a month. Another difference from
earlier studies was that only offenders who
said they preferred opioid-free treatments
like naltrexone to opioid-maintenance
treatments like methadone were allowed to
join the trial. Across five sites and over
nearly five years, 308 offenders were
randomly allocated, on average about 13 per
site per year, perhaps indicative of
naltrexone’s niche applicability. Over the 24
weeks of treatment the intention was to
renew the injections every four weeks.
Among this sample selected to be friendly to
the treatment, 77% of intended
administrations were completed. During the
treatment phase the proportion of
participants who relapsed to a period of
opioid use was 43% aided by naltrexone and
64% without; other measures consistently
confirmed a naltrexone-aided reduction in
opioid use. However, these impacts were no
longer apparent between six and 12 months
after treatment ended. Neither during
treatment was there any impact on
reimprisonment rates. Importantly, there
were no overdoses among the naltrexone
patients including periods after treatment
had ended, but 12 in the usual-treatment
comparators.
A non-randomised pilot study at the same
sites also seemed to recruit few participants.
The site which made the largest contribution
recruited 35 out of 336 potential
participants. Across all five sites there were
61 participants. At the sites where this was
the intended regimen, four in ten of the
offenders under criminal justice supervision
completed all six monthly injections of
long-acting naltrexone and on average four
of the six injections were administered. Just
one of the 26 offenders who completed their
treatment tested positive for opioid use at
the end of the six months of treatment.
Another non-randomised study was based on
routinely collected records of how patients
with alcohol and/or opioid use problems
progressed after agreeing to different
treatments while under community
supervision by the criminal justice system in
the US state of Missouri. Among offenders
who chose or agreed to it, long-acting
naltrexone seems to have helped support an
improvement in rates of abstinence from
alcohol and other drugs over three times
that for psychosocial treatment only, over
four times that for oral naltrexone, and over
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10 times that for buprenorphine
maintenance. There was, however, no
evidence that long-acting naltrexone was
associated with fewer arrests or more
patients gaining employment. These findings
remained after adjusting for known and
unknown differences between the patients
who received different treatments, but
nevertheless they could at least partly
reflect pre-existing differences in the
offenders who entered the different
treatments or in their situations, especially
the likelihood that those committed to
abstinence were routed towards and/or were
prepared to accept naltrexone injections.
Whether long-acting naltrexone’s advantage
remained after treatment ended was not
reported.
Leaving prison
Released in 2015 were the findings of a trial
of long-acting naltrexone administered in jail
immediately before release plus renewal four
weeks later, an attempt to prevent the
typically rapid (and dangerous) relapse to
opioid use among formerly dependent
prisoners. That it took over three years to
find the 34 prisoners in New York City’s jails
who joined the study, and that no women
could be included, seems to indicate that
among prisoners who have access to
methadone and allied treatments, the
demand for long-acting naltrexone is small –
participants could neither be in nor planning
to enter methadone or buprenorphine
maintenance treatments.
All 34 trial participants were offered brief
counselling and referral to treatment
services, and 17 were randomly allocated to
the additional naltrexone programme. All but
two of the 17 allocated to naltrexone were
injected with the drug. One was retained in
prison, leaving 16 who could be assessed
after release. Of these, 12 also accepted the
second injection. During the first four weeks
after release, 15 of the 17 (88%)
no-naltrexone offenders had relapsed to
opioid use compared to just six of 16 (38%)
offered naltrexone, a large and statistically
significant advantage for naltrexone unlikely
to have occurred by chance. Across the eight
post-release weeks assessed by the study,
over 90% of no-naltrexone patients relapsed
compared to half offered naltrexone. The
results showed that among (formerly)
opiate-dependent prisoners prepared to
accept this treatment, and for whom
maintenance prescribing is unwanted or
unavailable, long-acting naltrexone is
greatly superior to usual care in preventing
return to regular opioid use in the weeks
immediately after release. Additional
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recovery support was offered to the
naltrexone patients before their release,
which may also have partly accounted for
their doing better on release. A worrying
finding was that many more former
prisoners offered naltrexone injected drugs
after release from prison – 25% versus 6%
of the no-naltrexone control group. Also,
slightly more had used cocaine (56% versus
47%) and only slightly fewer had been
returned to prison (31% v. 41%). Given the
small size of the sample, none of these
differences were statistically significant, but
they do seem to suggest that while they
restricted use of heroin or other illegal
opioids, naltrexone injections did not control
other forms of drug use and did little to
stabilise other aspects of the patients’ lives.
The US trial described above tested
naltrexone injections against no medication
rather than against what may be considered
the ‘gold standard’ approach of offering
methadone or buprenorphine maintenance
in prison and seamlessly continuing it on
release. However, a Norwegian study did
make this comparison. In the month
preceding their release date, prisoners
dependent on opiates before their sentences
were randomly allocated either to
methadone maintenance or to a naltrexone
implant whose effects last for six months. Of
the 111 inmates who qualified for the trial,
most refused to participate, usually because
they intended to build on their enforced
break from opiates by remaining abstinent
on release. Of the 44 who did join the trial,
just 11 started methadone treatment in
prison and 16 were implanted with
naltrexone (seven of the 23 allocated to
naltrexone refused implantation). Compared
to before their imprisonment, across the 44
offenders on average in the six months after
release use of heroin and illicit
benzodiazepines had fallen substantially, but
not by significantly more among those
allocated to methadone versus naltrexone.
Even if long-acting naltrexone and
methadone are of equivalent effectiveness
among those prepared to be randomised to
either treatment, methadone is likely to be
more acceptable to greater range of opioid-
dependent prisoners. Unless incentivised in
some way – for example, by offering early
release – it seems likely that naltrexone
injections will be accepted only by prisoners
who, though dependent on opiate-type drugs
before their sentence, are prepared to
commit to a month without being able to
experience the effects of these drugs, yet
are not confident they can resist re-addiction
on leaving prison – an unusual combination.
An often false confidence in their
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determination and ability to build on prison
by starting an opioid-free life on release
leads many patients to reject medication of
any kind.
 Close supplementary text
Guidance
Efficacy and ethical considerations should come
together in guidance for practitioners and
service planners, but in the UK there is no
guidance specific to offenders. Last published
in 2017, the so-called ‘Orange guidelines’ for
clinicians involved in treating problem drug
use said of naltrexone:
• Among highly motivated patients provided
with adequate supervision, naltrexone can help
to maintain abstinence.
• Naltrexone should usually be used only after
a patient is opioid-free (verified by testing for
the presence of opioids).
• The impact of naltrexone may be enhanced
by additional support from a keyworker or
group, allowing service users to discuss any
issues related to sustaining abstinence.
• Its effectiveness should be reviewed
regularly and if opioid use becomes apparent,
discontinuation of naltrexone should be
considered.
In this the guidelines echo recommendations
from Britain’s National Institute for Health and
Care Excellence (NICE) that the drug is
suitable for detoxified patients who are highly
motivated to remain in an abstinence
programme, and should be administered under
adequate supervision as part of a programme
of supportive care to people who have been
fully informed of the risks. Despite an
unpromising record among the generally
randomly allocated patients in clinical trials,
NICE’s experts were convinced that among
selected individuals and in the recommended
circumstances, naltrexone can greatly aid
abstinence from opiate-type drugs with
associated improvements in the patient’s
quality of life. The World Health Organization
is clear that the post-treatment overdose risk
means naltrexone is best reserved for patients
who have a reasonable chance of remaining
abstinent, and that those severely dependent
should be cautious about embarking on the
treatment.
Specifically in relation to long-acting products,
an Effectiveness Bank hot topic concluded that
the clearest candidates for naltrexone implants
and injections are patients motivated to return
to a life without opiate-type drugs, who have
the resources, stability and support to sustain
this, are unlikely simply to use other drugs
instead, but who when free to experience
opiates, cannot resist them. Long-acting
formulations may also be considered for
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unstable patients at very high risk of overdose,
but who will not accept or do poorly in
substitute prescribing programmes. Other
candidates might include those unwilling or
unable to accept daily supervised consumption
if this is a requirement of being prescribed
substitute medications.
Unresolved questions
This introduction to the ethics and
effectiveness of naltrexone treatment for
offenders has raised but not resolved questions
for you to ponder, including: Is it OK to force
this treatment on the unwilling in their own
interests and that of their families and the
broader society, because once freed of their
addiction, this will extend the patient’s
autonomy rather than restrict it? Or only OK if
the offender can choose naltrexone as part of a
less onerous sentence than they would
otherwise have been given? Do we have
enough evidence that naltrexone-based
treatment works to feel comfortable about
pressurising anyone to accept it? Should we
also offer better established alternatives like
methadone maintenance, even if this means
naltrexone will rarely be chosen, and even if
methadone-maintained patients commonly
break the law by taking heroin once in a
while? Are we missing a
trick by not more widely
forcing or pressuring
opioid-dependent offenders
to take naltrexone under




after all, force an
interruption in regular
opioid use which may not
be achievable by any other
feasible means, and which
could be used to embed opioid-free ways of
coping. Or is this an ethically and perhaps also
physically dangerous subversion of treatment
to criminal justice ends when medicine is
supposed to prioritise the patient’s welfare?
But perhaps this is – despite their contrary
wishes – the best way to safeguard some
patients’ welfare, rather than leaving them
(and those around them) to descend deeper
into a destructive addiction – like forcibly
holding back someone about to walk off the
edge of a cliff, even if that is what they choose
to do?
Thanks for their comments on this entry to Colin Brewer,
a psychiatrist based in England. Commentators bear no
responsibility for the text including the interpretations
and any remaining errors.
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